Table 2 LI-RADS features and categories of iCCA and HCC in the high-risk population

Major features

 Tumor size (cm)^†

4.7 [3.5, 6.0]

5.0 [3.7, 6.4]

0.234

/

 Non-rim APHE

16 (15.0)

88 (82.2)

< 0.001^*

0.944

 Non-peripheral washout

8 (7.5)

84 (78.5)

< 0.001^*

0.886

 Enhancing capsule

14 (13.1)

101 (94.4)

< 0.001^*

0.785

LR-TIV

 Tumor in vein

2 (1.9)

12 (11.2)

0.006^*

0.788

LR-M

 Any targetoid features

91 (85.0)

21 (19.6)

< 0.001^*

0.897

 Rim APHE

79 (73.8)

19 (17.8)

< 0.001^*

0.830

 Peripheral washout

3 (2.8)

1 (0.9)

0.621

0.660

 Delayed central enhancement

25 (23.4)

5 (4.7)

< 0.001^*

0.920

 Targetoid diffusion restriction

58 (54.2)

4 (3.7)

< 0.001^*

0.855

 Infiltrative appearance

20 (18.7)

11 (10.3)

0.080

0.706

 Marked diffusion restriction

70 (65.4)

76 (71.0)

0.378

0.789

 Severe necrosis or ischemia

23 (21.5)

70 (65.4)

< 0.001^*

0.914

Ancillary features favoring HCC in particular

 Non-enhancing capsule

1 (0.9)

3 (2.8)

0.621

0.855

 Nodule-in-nodule

1 (0.9)

6 (5.6)

0.119

0.921

 Mosaic architecture

1 (0.9)

28 (26.2)

< 0.001^*

0.761

 Fat in mass, more than adjacent liver

0 (0)

29 (27.1)

< 0.001^*

0.937

 Blood products in mass

2 (1.9)

44 (41.1)

< 0.001^*

0.803

Ancillary features favoring malignancy, not HCC in particular

 US visibility as discrete nodule

102 (95.3)

105 (98.1)

0.445

/

 Corona enhancement

63 (58.9)

49 (45.8)

0.055

0.785

 Fat sparing in solid mass

0 (0)

1 (0.9)

0.999

1.000

 Iron sparing in solid mass

5 (4.7)

18 (16.8)

0.004^*

0.951

 Restricted diffusion

106 (99.1)

106 (99.1)

0.999

0.798

 Mild-moderate T2 hyperintensity

64 (59.8)

57 (53.3)

0.334

0.744

LI-RADS categories

< 0.001^*

/

 LR-4

15 (14.0)

1 (0.9)

 LR-5

1 (0.9)

78 (72.9)

 LR-M

89 (83.2)

16 (15.0)

 LR-TIV

2 (1.9)

12 (11.2)